Literature DB >> 34962990

Frequent Development of Broadly Neutralizing Antibodies in Early Life in a Large Cohort of Children With Human Immunodeficiency Virus.

Amanda Lucier1, Youyi Fong2, Shuk Hang Li1, Maria Dennis1, Joshua Eudailey1, Ashley Nelson1, Kevin Saunders1, Coleen K Cunningham1,3, Elizabeth McFarland4, Ross McKinney1, M Anthony Moody1, Celia LaBranche1, David Montefiori1, Sallie R Permar1,5, Genevieve G Fouda1.   

Abstract

BACKGROUND: Recent studies have indicated that broadly neutralizing antibodies (bnAbs) in children may develop earlier after human immunodeficiency virus (HIV) infection compared to adults.
METHODS: We evaluated plasma from 212 antiretroviral therapy-naive children with HIV (1-3 years old). Neutralization breadth and potency was assessed using a panel of 10 viruses and compared to adults with chronic HIV. The magnitude, epitope specificity, and immunoglobulin (Ig)G subclass distribution of Env-specific antibodies were assessed using a binding antibody multiplex assay.
RESULTS: One-year-old children demonstrated neutralization breadth comparable to chronically infected adults, whereas 2- and 3-year-olds exhibited significantly greater neutralization breadth (P = .014). Likewise, binding antibody responses increased with age, with levels in 2- and 3-year-old children comparable to adults. Overall, there was no significant difference in antibody specificities or IgG subclass distribution between the pediatric and adult cohorts. It is interesting to note that the neutralization activity was mapped to a single epitope (CD4 binding site, V2 or V3 glycans) in only 5 of 38 pediatric broadly neutralizing samples, which suggests that most children may develop a polyclonal neutralization response.
CONCLUSIONS: These results contribute to a growing body of evidence suggesting that initiating HIV immunization early in life may present advantages for the development of broadly neutralizing antibody responses.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  antibodies; broad neutralization; pediatric HIV

Mesh:

Substances:

Year:  2022        PMID: 34962990      PMCID: PMC9113503          DOI: 10.1093/infdis/jiab629

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   7.759


  38 in total

1.  ACTG 152: new insights into pediatric antiretroviral therapy.

Authors:  J Bowersox
Journal:  NIAID AIDS Agenda       Date:  1996-03

2.  Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1.

Authors:  O Scharf; H Golding; L R King; N Eller; D Frazier; B Golding; D E Scott
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques.

Authors:  Bonnie Phillips; Genevieve G Fouda; Josh Eudailey; Justin Pollara; Alan D Curtis; Erika Kunz; Maria Dennis; Xiaoying Shen; Camden Bay; Michael Hudgens; David Pickup; S Munir Alam; Amir Ardeshir; Pamela A Kozlowski; Koen K A Van Rompay; Guido Ferrari; M Anthony Moody; Sallie Permar; Kristina De Paris
Journal:  Clin Vaccine Immunol       Date:  2017-10-05

4.  Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals.

Authors:  Georgia D Tomaras; James M Binley; Elin S Gray; Emma T Crooks; Keiko Osawa; Penny L Moore; Nancy Tumba; Tommy Tong; Xiaoying Shen; Nicole L Yates; Julie Decker; Constantinos Kurt Wibmer; Feng Gao; S Munir Alam; Philippa Easterbrook; Salim Abdool Karim; Gift Kamanga; John A Crump; Myron Cohen; George M Shaw; John R Mascola; Barton F Haynes; David C Montefiori; Lynn Morris
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

5.  Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.

Authors:  S E Starr; C V Fletcher; S A Spector; F H Yong; T Fenton; R C Brundage; D Manion; N Ruiz; M Gersten; M Becker; J McNamara; L M Mofenson; L Purdue; S Siminski; B Graham; D M Kornhauser; W Fiske; C Vincent; H W Lischner; W M Dankner; P M Flynn
Journal:  N Engl J Med       Date:  1999-12-16       Impact factor: 91.245

6.  A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.

Authors:  Laura M Walker; Melissa D Simek; Frances Priddy; Johannes S Gach; Denise Wagner; Michael B Zwick; Sanjay K Phogat; Pascal Poignard; Dennis R Burton
Journal:  PLoS Pathog       Date:  2010-08-05       Impact factor: 6.823

7.  IgG subclass responses to human immunodeficiency virus-1 antigens: lack of IgG2 response to gp41 correlates with clinical manifestation of disease.

Authors:  R B Lal; I M Heiba; R R Dhawan; E S Smith; P L Perine
Journal:  Clin Immunol Immunopathol       Date:  1991-02

8.  Early development of broadly neutralizing antibodies in HIV-1-infected infants.

Authors:  Leslie Goo; Vrasha Chohan; Ruth Nduati; Julie Overbaugh
Journal:  Nat Med       Date:  2014-05-25       Impact factor: 53.440

9.  HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.

Authors:  Zanele Ditse; Maximilian Muenchhoff; Emily Adland; Pieter Jooste; Philip Goulder; Penny L Moore; Lynn Morris
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

10.  Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection.

Authors:  Maximilian Muenchhoff; Emily Adland; Owen Karimanzira; Carol Crowther; Matthew Pace; Anna Csala; Ellen Leitman; Angeline Moonsamy; Callum McGregor; Jacob Hurst; Andreas Groll; Masahiko Mori; Smruti Sinmyee; Christina Thobakgale; Gareth Tudor-Williams; Andrew J Prendergast; Henrik Kloverpris; Julia Roider; Alasdair Leslie; Delane Shingadia; Thea Brits; Samantha Daniels; John Frater; Christian B Willberg; Bruce D Walker; Thumbi Ndung'u; Pieter Jooste; Penny L Moore; Lynn Morris; Philip Goulder
Journal:  Sci Transl Med       Date:  2016-09-28       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.